(Q38242979)

31 August 2017

Hydralazine-valproate: a repositioned drug combination for the epigenetic therapy of cancer (English)

1 reference

31 August 2017

Alfonso Dueñas-Gonzalez

1

1 reference

31 August 2017

Jaime Coronel

2

1 reference

31 August 2017

Lucely Cetina

3

1 reference

31 August 2017

Aurora González-Fierro

4

1 reference

31 August 2017

Alma Chavez-Blanco

5

1 reference

31 August 2017

Lucia Taja-Chayeb

6

1 reference

31 August 2017

language of work or name

English

0 references

publication date

25 August 2014

1 reference

Expert Opinion on Drug Metabolism & Toxicology

31 August 2017

1 reference

31 August 2017

10

1 reference

31 August 2017

10

1 reference

31 August 2017

1433-1444

1 reference

Cancer genetics and epigenetics: two sides of the same coin?

31 August 2017

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2014.947263

Structure and function of mammalian DNA methyltransferases.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2014.947263

Multiple functions of dynamic histone acetylation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2014.947263

DNA methylation profiling in the clinic: applications and challenges

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2014.947263

Cancer epigenomics: DNA methylomes and histone-modification maps

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2014.947263

The analysis of histone modifications

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2014.947263

Histone proteomics and the epigenetic regulation of nucleosome mobility

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2014.947263

Interplay between microRNAs and the epigenetic machinery: an intricate network

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2014.947263

Tet proteins can convert 5-methylcytosine to 5-formylcytosine and 5-carboxylcytosine

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2014.947263

Reprogramming DNA methylation in the mammalian life cycle: building and breaking epigenetic barriers

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2014.947263

Cancer drug discovery by repurposing: teaching new tricks to old dogs

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2014.947263

The prince and the pauper. A tale of anticancer targeted agents

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2014.947263

Cancer chemoprevention by targeting the epigenome.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2014.947263

Rosiglitazone prevents the progression of preinvasive lung cancer in a murine model

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2014.947263

Hydralazine for treatment of severe hypertension in pregnancy: meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2014.947263

Valproic acid. Review of a new antiepileptic drug

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2014.947263

Valproic acid defines a novel class of HDAC inhibitors inducing differentiation of transformed cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2014.947263

Molecular modeling and molecular dynamics studies of hydralazine with human DNA methyltransferase 1.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2014.947263

Novel and selective DNA methyltransferase inhibitors: Docking-based virtual screening and experimental evaluation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2014.947263

Hydralazine may induce autoimmunity by inhibiting extracellular signal-regulated kinase pathway signaling

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2014.947263

Reactivation of epigenetically silenced genes by DNA methyltransferase inhibitors: basic concepts and clinical applications

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2014.947263

Hydralazine inhibits human cervical cancer cell growth in vitro in association with APC demethylation and re-expression

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2014.947263

Epigenetic and HIF-1 regulation of stanniocalcin-2 expression in human cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2014.947263

Association between CpG island methylation of the WWOX gene and its expression in breast cancers

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2014.947263

Hydralazine-induced promoter demethylation enhances sarcoplasmic reticulum Ca2+ -ATPase and calcium homeostasis in cardiac myocytes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2014.947263

Induction of a trophoblast-like phenotype by hydralazine in the p19 embryonic carcinoma cell line

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2014.947263

Global DNA hypermethylation-associated cancer chemotherapy resistance and its reversion with the demethylating agent hydralazine

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2014.947263

DNA methylation-independent reversion of gemcitabine resistance by hydralazine in cervical cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2014.947263

Histone deacetylase is a direct target of valproic acid, a potent anticonvulsant, mood stabilizer, and teratogen

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2014.947263

Histone deacetylase is a target of valproic acid-mediated cellular differentiation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2014.947263

Valproic acid alters chromatin structure by regulation of chromatin modulation proteins

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2014.947263

Evolving anticancer drug valproic acid: insights into the mechanism and clinical studies.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2014.947263

Dose-response relationships with antihypertensive drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2014.947263

Valproic acid pathway: pharmacokinetics and pharmacodynamics

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2014.947263

Valproic acid toxicity: overview and management

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2014.947263

A phase I study of hydralazine to demethylate and reactivate the expression of tumor suppressor genes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2014.947263

Histone acetylation and histone deacetylase activity of magnesium valproate in tumor and peripheral blood of patients with cervical cancer. A phase I study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2014.947263

A proof-of-principle study of epigenetic therapy added to neoadjuvant doxorubicin cyclophosphamide for locally advanced breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2014.947263

Can the state of cancer chemotherapy resistance be reverted by epigenetic therapy?

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2014.947263

A phase II study of epigenetic therapy with hydralazine and magnesium valproate to overcome chemotherapy resistance in refractory solid tumors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2014.947263

Antineoplastic effects of the DNA methylation inhibitor hydralazine and the histone deacetylase inhibitor valproic acid in cancer cell lines

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2014.947263

Up-regulation of HLA class-I antigen expression and antigen-specific CTL response in cervical cancer cells by the demethylating agent hydralazine and the histone deacetylase inhibitor valproic acid

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2014.947263

A double-blind, placebo-controlled, randomized phase III trial of chemotherapy plus epigenetic therapy with hydralazine valproate for advanced cervical cancer. Preliminary results

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2014.947263

Neoadjuvant vinorelbine/epirubicin (VE) versus standard adriamycin/cyclophosphamide (AC) in operable breast cancer: analysis of response and tolerability in a randomised phase III trial (TOPIC 2).

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2014.947263

A randomised pilot Phase II study of doxorubicin and cyclophosphamide (AC) or epirubicin and cyclophosphamide (EC) given 2 weekly with pegfilgrastim (accelerated) vs 3 weekly (standard) for women with early breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2014.947263

Hematologic toxicity of sodium valproate

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2014.947263

Nitroso-urea-cisplatin-based chemotherapy associated with valproate: increase of haematologic toxicity

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2014.947263

Routine management of locally advanced cervical cancer with concurrent radiation and cisplatin. Five-year results

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2014.947263

Epigenetic therapy of hematological malignancies: where are we now?

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2014.947263

In vitro basis for treatment with hypomethylating agents and histone deacetylase inhibitors: can epigenetic changes be used to monitor treatment?

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2014.947263

Hydralazine and magnesium valproate as epigenetic treatment for myelodysplastic syndrome. Preliminary results of a phase-II trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2014.947263

Histone deacetylase inhibitors profoundly decrease proliferation of human lymphoid cancer cell lines.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2014.947263

Epigenetic profiling of cutaneous T-cell lymphoma: promoter hypermethylation of multiple tumor suppressor genes including BCL7a, PTPRG, and p73

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2014.947263

Epigenetic targets in hematological malignancies: combination therapies with HDACis and demethylating agents

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2014.947263

Improved survival with bevacizumab in advanced cervical cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2014.947263

Treatment of poor-risk myelodysplastic syndromes and acute myeloid leukemia with a combination of 5-azacytidine and valproic acid

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2014.947263

Valproic acid at therapeutic plasma levels may increase 5-azacytidine efficacy in higher risk myelodysplastic syndromes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2014.947263

Comparative Effectiveness Questions in Oncology

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2014.947263

10.1517/17425255.2014.947263

21 January 2018

Identifiers

DOI

1 reference

31 August 2017

1 reference